Author’s response to reviews

Title: CDK1 and CCNB1 as potential diagnostic markers of rhabdomyosarcoma: Validation following bioinformatics analysis

Authors:
Qianru Li (1509094295@qq.com)
Liang Zhang (451657706@qq.com)
Jinfang Jiang (shzjjF@163.com)
Yangyang Zhang (472989983@qq.com)
Xiaomeng Wang (dream914@163.com)
Qiaochu Zhang (372193745@qq.com)
Yang Wang (499965529@qq.com)
Chunxia Liu (liuliu2239@sina.com)
Feng Li (lifeng7855@126.com)

Version: 4 Date: 04 Dec 2019

Author’s response to reviews:

Arwa Tawfiq
BMC Medical Genomics

04 Dec 2019

Dear Arwa Tawfiq,

Re: Manuscript No. MGNM-D-19-00227R3, Submission of the revised manuscript entitled “CDK1 and CCNB1 as potential diagnostic markers of rhabdomyosarcoma: Validation following bioinformatics analysis”.

Thank you very much for your letter, questions and the editorial and reviewers' comments which we found very helpful in improving our manuscript. We have revised the paper according to the comments in a point-by-point format as shown below.

In addition, all authors declare no conflict of interest to report.
We hope the revised manuscript is satisfactory and suitable for publication in your journal. Please let us know if further revisions are needed.

Sincerely yours,

Chunxia Liu, MD, PhD
Department of Pathology
Shihezi University School of Medicine
North 2nd Road
Shihezi, Xinjiang 832002
China
Phone: +86-138-9950-2239
E-mail: liuliu2239@sina.com

Responses to the Assistant Editor Comments:

1. Availability of data and materials

   a) Please note that BMC mandates data deposition for the following:

   • Protein sequences
   • DNA and RNA sequences
   • DNA and RNA sequencing data
   • Genetic polymorphisms
   • Linked genotype and phenotype data
   • Macromolecular structure
   • Microarray data (must be MIAME compliant)
   • Crystallographic data for small molecules

   As such, we ask that you please provide the relevant accession numbers if your data has been deposited into a data bank or the appropriate web links if the data has been uploaded into a repository. If the data has not yet been deposited, please do so and provide the relevant information needed to access it in the ‘Availability of data and materials’ section in your manuscript. Please ensure all data is already released and that any accession numbers/web links are in the ‘Availability of Data and Materials’ in their final form, and that all links and accessions allow access to public data.
Your data availability statement can take the following form: “The datasets generated and/or analysed during the current study are available in the [NAME] repository, [PERSISTENT WEB LINK OR ACCESSION NUMBER TO DATASETS].”

b) Please provide direct web links or accession numbers to the datasets analysed in your study, including the full name of the repository or database from which these datasets were obtained. If the datasets are not publicly available, please provide a valid reason and include further detail in the Availability of data and materials section of your manuscript in regard to who should be contacted and their contact details or where to apply for permissions to obtain access to the raw data.

Response: Thank you for your comment. In this study, 82 samples were obtained from existing datasets in the GEO database. The data set contains GSE16382, GSE66533, GSE39454, GSE17674 and GSE38417. The manuscript states: "The required original data were gained from Gene Expression Omnibus (GEO) database (www.ncbi.nlm.nih.gov/geo/). We screened 82 samples, including 66 samples of RMS patient tissues (GSE16382 [N = 8] [13] and GSE66533 [N = 58] [14]) and 16 samples of normal striated muscle tissues (GSE39454 [N = 5] [15], GSE17674 [N = 5] [16] and GSE38417 [N = 6]). All data were obtained on the GPL570 platform to ensure consistent data processing.” (In the Methods section of the text of the manuscript, line 28, 29, page 3; line1-3, page 4) and “The original data for this study are from the datasets GSE16382, GSE66533, GSE39454, GSE17674 and GSE38417.” (In the Availability of data and materials section of the text of the manuscript, line 25-27, page 12)

2. Role of funding body

Please provide more details regarding the specific role of the funding body in your study. If the funding body only provided the financial means to allow the authors to carry out the study, please state “The funding body played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript” and include this statement in the Funding section of your manuscript.

However, if the funding body took part in the design of the study and collection, analysis, and interpretation of data, and the writing of the manuscript, this must be stated in the Competing Interests section of your manuscript.

Response: Thank you for this comment. In the revised manuscript, according to your suggestion, we added "The funding institutions provide only financial means that allow authors to carry out the study, and are not involved in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript "in the funding section. (In the Funding section of the text of the manuscript, line 6-8, page 13)
3. Authors’ contributions

Please consider the list of authors as it currently stands with reference to our guidelines regarding qualification for authorship (http://www.biomedcentral.com/submissions/editorial-policies#authorship).

Currently, the contributions of author DMG and KM do not automatically qualify them for authorship. In the section “Authors’ contributions”, please provide further clarifications on their contributions, and see our guidelines for authorship below.

An 'author' is generally considered to be someone who has made substantive intellectual contributions to a published study. Authors are expected to fulfil the criteria below (adapted from McNutt et al., Proceedings of the National Academy of Sciences, Feb 2018, 201715374; DOI: 10.1073/pnas.1715374115; licensed under CC BY 4.0):

Each author is expected to have made substantial contributions to the conception OR design of the work; OR the acquisition, analysis, OR interpretation of data; OR the creation of new software used in the work; OR have drafted the work or substantively revised it

AND to have approved the submitted version (and any substantially modified version that involves the author's contribution to the study);

AND to have agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

Please note that acquisition of funding, collection of data or general supervision of the research group, alone, does not usually justify authorship. You may acknowledge individuals who assist in the acquisition of funding or of data or supervise the research group in the Acknowledgments section of your manuscript.

If you wish to amend the list of authors, please use the standardised form which you and your co-authors must complete. The authorship change form can be found at the following link: https://resource-cms.springernature.com/springer-cms/rest/v1/content/7454878/data/v5. All instructions can be found on the form, please treat the 'current authorship' section as the original authorship. Please return the form within 14 days by email to the Editorial Office with all author signatures (including those newly added/removed).

Response: Thank you for this comment. In the revised manuscript, based on your suggestions, we have modified the Authors’ contributions as follows: "CL, QL, LZ and FL design research; CL, FL, QL and JJ participated in the design, implementation and analysis of the experiment; QL, LZ, YZ, XW, QZ, YL participated in the data collection, analysis and interpretation; QL drafted the work and made substantial changes. All authors participated in the manuscript modification proposal and approved the final version.” (In the Authors’ contributions section of the text of the manuscript, line10-13, page 12)
4. At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Should you wish to respond to these revision requests, please put your responses to the reviewers'/editors’ comments in the Response to Reviewers box in Editorial Manager. Please do not upload a separate letter.

Recipients of this email are registered users within the Editorial Manager database for this journal. We will keep your information on file to use in the process of submitting, evaluating and publishing a manuscript. For more information on how we use your personal details please see our privacy policy at https://www.springernature.com/production-privacy-policy. If you no longer wish to receive messages from this journal or you have questions regarding database management, please contact the Publication Office at the link below.

Response: Thank you for this comment. The new manuscript we uploaded is a final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colors. All relevant tables/figures/additional files are also clean versions.